Dataset Information


Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway.



Despite the impressive efficacy of crizotinib for the treatment of ALK-positive non-small cell lung cancer, patients invariably develop therapeutic resistance. Suppression of the IGF-1R signaling pathway may abrogate this acquired mechanism of drug resistance to crizotinib. Metformin, a widely used antidiabetic agent, may reverse crizotinib resistance through inhibition of IGF-1R signaling.


The present study revealed that metformin effectively increased the sensitivity of both crizotinib-sensitive and -resistant non-small cell lung cancer cells to crizotinib, as evidenced by decreased proliferation and invasion and enhanced apoptosis. Metformin reduced IGF-1R signaling activation in crizotinib-resistant cells. Furthermore, the addition of IGF-1 to crizotinib-sensitive H2228 cells induced crizotinib resistance, which was overcome by metformin.

Experimental design

The effects of metformin to reverse crizotinib resistance were examined in vitro by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT), invasion assay, ki67 incorporation assay, flow cytometry analysis, Western blot analysis, and colony-forming assay.


Metformin may be used in combination with crizotinib in ALK+ NSCLC patients to overcome crizotinib resistance and prolong survival.


PROVIDER: S-EPMC5085167 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5654778 | BioStudies
2013-01-01 | S-EPMC5528442 | BioStudies
2015-01-01 | S-EPMC5999905 | BioStudies
2014-01-01 | S-EPMC4159407 | BioStudies
2018-01-01 | S-EPMC5783011 | BioStudies
1000-01-01 | S-EPMC5912135 | BioStudies
2019-01-01 | S-EPMC7193943 | BioStudies
2017-01-01 | S-EPMC5715105 | BioStudies
1000-01-01 | S-EPMC5601691 | BioStudies
2016-01-01 | S-EPMC5003168 | BioStudies